JP5661458B2 - ５ＨＴＲ２Ｃ ｍＲＮＡ編集機構の変更のマーカーとしての５ＨＴＲ２Ｃおよび／またはＡＤＡＲを発現する細胞を含有する末梢組織サンプル、ならびにその適用 - Google Patents

５ＨＴＲ２Ｃ ｍＲＮＡ編集機構の変更のマーカーとしての５ＨＴＲ２Ｃおよび／またはＡＤＡＲを発現する細胞を含有する末梢組織サンプル、ならびにその適用 Download PDF

Info

Publication number
JP5661458B2
JP5661458B2 JP2010511663A JP2010511663A JP5661458B2 JP 5661458 B2 JP5661458 B2 JP 5661458B2 JP 2010511663 A JP2010511663 A JP 2010511663A JP 2010511663 A JP2010511663 A JP 2010511663A JP 5661458 B2 JP5661458 B2 JP 5661458B2
Authority
JP
Japan
Prior art keywords
adar1
mrna
editing
5htr2c
adar2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010511663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528672A (ja
JP2010528672A5 (enExample
Inventor
ディナ、ワイスマン
ジャン‐フランソワ、プジョール
ローラン、バンサン
ローラン、カバレ
ジョン、マン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocortech SpA
Original Assignee
Biocortech SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocortech SpA filed Critical Biocortech SpA
Publication of JP2010528672A publication Critical patent/JP2010528672A/ja
Publication of JP2010528672A5 publication Critical patent/JP2010528672A5/ja
Application granted granted Critical
Publication of JP5661458B2 publication Critical patent/JP5661458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2010511663A 2007-06-13 2008-06-13 ５ＨＴＲ２Ｃ ｍＲＮＡ編集機構の変更のマーカーとしての５ＨＴＲ２Ｃおよび／またはＡＤＡＲを発現する細胞を含有する末梢組織サンプル、ならびにその適用 Active JP5661458B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94368507P 2007-06-13 2007-06-13
US60/943,685 2007-06-13
US2323908P 2008-01-24 2008-01-24
US61/023,239 2008-01-24
PCT/EP2008/057519 WO2008152146A1 (en) 2007-06-13 2008-06-13 Peripherical tissue sample containing cells expressing the 5htr2c and/or adars as markers of the alteration of the mechanism of the 5htr2c mrna editing and its applications

Publications (3)

Publication Number Publication Date
JP2010528672A JP2010528672A (ja) 2010-08-26
JP2010528672A5 JP2010528672A5 (enExample) 2011-07-28
JP5661458B2 true JP5661458B2 (ja) 2015-01-28

Family

ID=39776384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010511663A Active JP5661458B2 (ja) 2007-06-13 2008-06-13 ５ＨＴＲ２Ｃ ｍＲＮＡ編集機構の変更のマーカーとしての５ＨＴＲ２Ｃおよび／またはＡＤＡＲを発現する細胞を含有する末梢組織サンプル、ならびにその適用

Country Status (6)

Country Link
EP (2) EP2162550B1 (enExample)
JP (1) JP5661458B2 (enExample)
CN (1) CN101743322B (enExample)
CA (1) CA2690909C (enExample)
ES (2) ES2952748T3 (enExample)
WO (1) WO2008152146A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202321A1 (en) 2008-12-17 2010-06-30 Biocortech Evaluation of the potential risk of drug induced mood disturbance and suicide:use of a dedicated platform
US11873531B2 (en) * 2010-06-24 2024-01-16 Alcediag Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
WO2011161253A1 (en) * 2010-06-24 2011-12-29 Biocortech Editing profiling of pde8a pre -mrna : use as specific biomarker of adars activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
CN102146119A (zh) * 2011-01-17 2011-08-10 山东大学齐鲁医院 一种小鼠表皮总蛋白的提取方法
JP7227006B2 (ja) * 2016-03-11 2023-02-21 アルスディアグ 活性化合物によって誘発される特定の効果を選択するための、ｒｎａ編集に基づくアルゴリズム及びインビトロの方法
US12084719B2 (en) * 2016-07-28 2024-09-10 Alcediag RNA editing as biomarkers for mood disorders test
CN110352244B (zh) * 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ 化学修饰的编辑rna的单链寡核苷酸
EP3819387A1 (en) * 2019-11-08 2021-05-12 Alcediag Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers
EP3819386A1 (en) * 2019-11-08 2021-05-12 Alcediag Diagnosing of mood disorders using blood rna editing biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763174A (en) * 1994-02-17 1998-06-09 The Wistar Institute Of Anatomy & Biology RNA editing enzyme and methods of use thereof
FR2842827B1 (fr) * 2002-07-26 2004-10-22 Biocortech NOUVELLE METHODE D'ANALYSE D'ACIDE NUCLEIQUE ET SON UTILISATION POUR EVALUER LE DEGRE D'EDITION DE L'ARNm DU RECEPTEUR 5-HT2c
WO2005087949A1 (en) * 2004-03-12 2005-09-22 Compugen Ltd. Systematic mapping of adenosine to inosine editing sites in the human transcriptome
GB0420873D0 (en) * 2004-09-20 2004-10-20 Curidium Ltd Methods of diagnosis
US20100008921A1 (en) * 2005-06-16 2010-01-14 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Target Adarb2 Proteins for Neurodegenerative Diseases

Also Published As

Publication number Publication date
EP3272881B1 (en) 2023-06-07
WO2008152146A1 (en) 2008-12-18
CA2690909C (en) 2022-01-18
JP2010528672A (ja) 2010-08-26
ES2952748T3 (es) 2023-11-03
CA2690909A1 (en) 2008-12-18
CN101743322A (zh) 2010-06-16
ES2646592T3 (es) 2017-12-14
EP2162550A1 (en) 2010-03-17
EP2162550B1 (en) 2017-08-09
EP3272881C0 (en) 2023-06-07
EP3272881A1 (en) 2018-01-24
CN101743322B (zh) 2014-12-24
EP3272881B9 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
JP5661458B2 (ja) ５ＨＴＲ２Ｃ ｍＲＮＡ編集機構の変更のマーカーとしての５ＨＴＲ２Ｃおよび／またはＡＤＡＲを発現する細胞を含有する末梢組織サンプル、ならびにその適用
JP5785697B2 (ja) Ｃｎｔｆ遺伝子多型に基づく、精神病および統合失調症の処置方法
Dracheva et al. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide
Haberman et al. Characterization of CpG island DNA methylation of impairment-related genes in a rat model of cognitive aging
JP2010528672A5 (enExample)
JP5846372B2 (ja) Ｄｒａｖｅｔ症候群の発症可能性の判定方法およびその利用
JP6644731B2 (ja) 気分障害および自殺を誘発する、薬剤の潜在的なリスクの評価：専用プラットフォームの使用
US20100184058A1 (en) Peripherical tissue sample containing cells expressing the 5htr2c and/or adars as markers of the alteration of the mechanism of the 5htr2c mrna editing and its applications
Donarum et al. Cognitive dysfunction in NFI knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex
JP2009131247A (ja) 脳炎または脳症の罹患リスク判定データの取得方法およびその利用、並びに熱性けいれんのてんかんへの移行リスク判定データの取得方法およびその利用
JP2008524999A (ja) 精神障害を治療するための組成物及び方法
Wu et al. c. 835-5T> G variant in SMN1 gene causes transcript exclusion of exon 7 and spinal muscular atrophy
JP2013529465A (ja) ＰＤＥ８ＡｍＲＮＡ前駆体の編集プロファイリング：治療効力および／もしくは有効性または潜在的薬物副作用を診断するため、ならびに予測および評価するための、ヒト組織における特異的バイオマーカーとしてのＡＤＡＲｓ活性の使用
KR101967880B1 (ko) 샤르코-마리-투스병 진단용 마커 및 그의 용도
Tsai et al. Genetic analysis of polymorphisms in the kalirin gene for association with age-at-onset in European Huntington disease patients
You et al. Lack of association between BDNF Val66Met gene polymorphism and late-onset depression in a Chinese Han population
Lin et al. A novel deletion mutation in GJB1 causes X‐linked Charcot–Marie–Tooth disease in a Han Chinese family
JPWO2004016785A1 (ja) アトピー性皮膚炎の検査方法
Vellingiri et al. Screening of mutations in PARK2 gene and Dopamine levels in Parkinson's disease (PD) patients in Coimbatore population, India
JP7088519B2 (ja) 側弯症の検査方法
KR101289114B1 (ko) 조기발병하는 상염색체 열성 축삭형 샤르코-마리-투스병의 원인 유전자로서 hadhb 돌연변이 유전자, 이를 이용한 상기 질병의 진단방법 및 진단용 조성물
JP4393148B2 (ja) 末梢型ベンゾジアゼピン受容体遺伝子解析によるストレス感受性の判断方法
KR20230138820A (ko) Mpz 유전자의 돌연변이를 포함하는, 신규한 샤르코-마리-투스병 진단용 바이오마커 및 이의 용도
JP2008306966A (ja) ジアゼパム結合阻害物質（ｄｂｉ）遺伝子の多型解析
Sharma et al. Role of TYR Gene Variants (Rs6482999 and Rs7123654) in Genetic Susceptibility to Vitiligo in Himachal Pradesh Population

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140901

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141203

R150 Certificate of patent or registration of utility model

Ref document number: 5661458

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250